Table 2 Malignancies in Clinical Trials of Maraviroc
| Â | ART Experienced | ART Naive | ||||||
|---|---|---|---|---|---|---|---|---|
Malignancy | MOTIVATE | Non-R5 MVC | MERIT | |||||
| Â | MVC QD | MVC BID | OBR | MVC QD | MVC BID | OBR | MVC | EFV |
Lymphoma | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 3 |
Kaposi Sarcoma | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 1 |
Other | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 3 |
| Â | ART Experienced | ART Naive | ||||||
|---|---|---|---|---|---|---|---|---|
Malignancy | MOTIVATE | Non-R5 MVC | MERIT | |||||
| Â | MVC QD | MVC BID | OBR | MVC QD | MVC BID | OBR | MVC | EFV |
Lymphoma | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 3 |
Kaposi Sarcoma | 1 | 2 | 3 | 0 | 0 | 0 | 0 | 1 |
Other | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 3 |